Genmab


Better-than-expected Q1 21; full-year guidance maintained

06/05/21 -"Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported better-than-expected sales in Q1 21 with the ex-US region leading the ..."

Pages
55
Language
English
Published on
06/05/21
You may also be interested by these reports :
10/06/21
When we last teased about Faes Farma (Add, Spain) in July 2020, the small pharma firm was under pressure due to lower demand for its anti-allergy / ...

10/06/21
By gaining 9% over last week, Roche (Add, Switzerland), the largest European pharma by market cap, set the sector on fire. This was overdue as shown ...

09/06/21
With COVID-19 vaccine programmes fast gaining pace, a gradual recovery is expected in the Anti-Histamine markets heading into H2 21, indicating ...

09/06/21
Recently, there has been a turnaround in Roche’s fortunes, with its share price outperforming peers. While, fundamentally, Roche had always been a ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO